Qiagen launches therascreen BRAF test

By LabPulse.com staff writers

April 16, 2020 -- Qiagen is launching a therascreen BRAF test as a companion diagnostic to Pfizer's targeted drug Braftovi in metastatic colorectal cancer.

The U.S. Food and Drug Administration (FDA) has approved the use of the therascreen BRAF V600E kit, a polymerase chain reaction (PCR) assay, as a companion diagnostic to Braftovi. The test will help identify which patients are eligible for treatment with Braftovi, a BRAF inhibitor.

Braftovi has been approved for use in combination with Erbitux in adults with previously treated metastatic colorectal cancer and who have a BRAF V600E mutation. Qiagen noted that in patients with primary and metastatic colorectal cancer, BRAF mutations (nearly always V600E) are found in up to 15% of patients; they are thought to be key drivers of tumor growth.

Qiagen gets FDA nod for syndromic SARS-CoV-2 test
Qiagen has received emergency use authorization from the U.S. Food and Drug Administration for its QIAstat-Dx diagnostic kit, a syndromic test for detecting...
Qiagen taps CEO, ships coronavirus tests to U.S.
Qiagen has made it official: Thierry Bernard has been named the company's permanent CEO after serving in an interim capacity since October 2019.
Qiagen boosts RNA extraction kit production
Qiagen is boosting its global production capacity for RNA nucleic extraction kits for use in detecting the novel coronavirus.
Qiagen, NuProbe partner on next-generation sequencing liquid biopsy
Qiagen and molecular diagnostics company NuProbe have entered into an agreement to develop noninvasive liquid biopsy tests for cancer diagnosis using...
Vendors, labs scramble to meet needs of coronavirus outbreak
The outbreak of the novel coronavirus is putting a strain on diagnostics manufacturers and clinical labs as they struggle to meet the need for more testing....

Copyright © 2020 LabPulse.com

Last Updated eh 4/30/2020 9:49:07 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.